HS-20122 / Jiangsu Hansoh Pharma - LARVOL DELTA

A Study of HS-20122 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=1050 | Not yet recruiting | Sponsor: Hansoh BioMedical R&D Company

New P1 trial • Solid Tumor

THE CLINICAL TRIAL APPROVAL FOR HS-20122 FOR INJECTION ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (HKEXnews) - "The board of directors (the 'Board') of Hansoh Pharmaceutical Group Company Limited (the 'Company' and together with its subsidiaries, the 'Group') is pleased to announce that, HS-20122 for injection, which is an antibody-drug conjugate (ADC) of the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China, which is intended to be investigated in clinical trials for advanced solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, or colorectal cancer."

New trial • Colorectal Cancer • Non Small Cell Lung Cancer • Squamous Cell Carcinoma of Head and Neck